Clinical trials / Wisconsin
Psychedelic and ketamine trials recruiting in Wisconsin
3 trials registered on ClinicalTrials.gov were recruiting at one or more sites in Wisconsin on 26 Oct 2026. By substance: Psilocybin 3. By condition: opioid use disorder 1.
From the ClinicalTrials.gov registry (US National Library of Medicine), read through its public API on 26 Oct 2026: studies marked as recruiting whose interventions name the substance. Titles, sponsors, phases, conditions and sites are the registry's own entries, written by the sponsors. We have not vetted any trial, and recruiting status changes; the registry record and the study team have the current eligibility rules.
Phase 1PsilocybinNCT04161066
Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine
- Conditions:
- Opioid Use Disorder
- Sponsor:
- University of Wisconsin, Madison
- Who:
- ages 21 Years to 65 Years, 10 participants planned
- University of Wisconsin, Madison, Wisconsin
Phase 1PsilocybinNCT05866471
The ENHANCE Study: taVNS and Psilocybin (ENHANCE)
- Conditions:
- Healthy; Psychedelic Experiences; Vagus Nerve Stimulation
- Sponsor:
- University of Wisconsin, Madison
- Who:
- ages 18 Years to 70 Years, 115 participants planned, accepts healthy volunteers
- University of Wisconsin - Madison, Madison, Wisconsin
Phase 1PsilocybinNCT06692192
The RECAP2 Study: Midazolam and Psilocybin
- Conditions:
- Psilocybin
- Sponsor:
- University of Wisconsin, Madison
- Who:
- ages 18 Years to 65 Years, 60 participants planned, accepts healthy volunteers
- UW School of Medicine and Public Health, Madison, Wisconsin